Agoracom Blog Home

Posts Tagged ‘EBITDA’

Mota Ventures $MOTA.ca Announces DTC Eligibility for Common Shares $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 9:32 AM on Thursday, April 23rd, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC / April 23, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTCPINK:PEMTF) (the “Company“) is pleased to announce that it has received approval from the Depository Trust Company (“DTC“) to make the Company’s common shares eligible to be electronically cleared and settled through DTC (“DTC Eligibility“).

DTC is a subsidiary of the Depository Trust and Clearing Corporation, a United States company that manages the electronic clearing and settlement of publicly traded companies. DTC Eligibility incorporates an electronic method of clearing securities that speeds up the receipt of stock and cash, and thus accelerates the settlement process for certain investors. DTC is a member of the U.S. Federal Reserve System, a limited-purpose trust company under New York State banking law and a registered clearing agency with the U.S. Securities and Exchange Commission.

In addition to trading over-the-counter in the United States under the ticker symbol “PEMTF”, the Company’s common shares continue to trade on the Canadian Securities Exchange under the symbol “MOTA” and on the Frankfurt Stock Exchange under the symbol “1WZ”.

“We are very pleased to have obtained DTC eligibility as it simplifies the process of investors and brokers trading and exchanging our stock in the United States, which will benefit Mota and our shareholders. I also expect that being DTC eligible will improve our overall liquidity and help to broaden our shareholder base in North America,” stated Ryan Hoggan, CEO of the Company.

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the Company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brands. Within Europe, its Satavida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Mota Ventures $MOTA.ca Raises $2.8 Million in Additional Private Placement $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 8:03 AM on Wednesday, April 22nd, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC / ACCESSWIRE / April 22, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTCPINK:PEMTF) (the “Company“) is pleased to announce that it has completed a further offering (the “Offering“) of 9,944,000 units (each, a “Unit“) by way of non-brokered private placement at a price of $0.28 per Unit for gross proceeds of $2,784,320. Each Unit consists of one common share of the Company, and one common share purchase warrant (each, a “Warrant“) exercisable to acquire an additional share at a price of $0.38 for a period of twenty-four months, expiring on April 21, 2022. When combined with the earlier offering completed by the Company on April 1, 2020, the Company has raised gross proceeds of $4,504,320.

The Company anticipates utilizing the proceeds of the Offering to further develop and market products in North America and Europe using its ecommerce sales channels, to satisfy compensation obligations owing to employees based on services provided to the Company and the satisfaction of performance metrics and for general working capital purposes. In connection with completion of the Offering, the Company has paid $75,120 and issued 262,857 common shares and 268,287 Warrants to certain arms-length parties who assisted in facilitating the Offering. The Company has also issued 142,857 Warrants to an arms-length consultant, as partial consideration for services provided to the Company.

All securities issued in connection with the Offering are subject to a four-month-and-one-day statutory hold period in accordance with applicable securities law.

About Mota Ventures Corp.

Mota Ventures is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value-added products from its Latin American operations and distribute it both domestically and internationally. Its existing operations in Colombia consist of a 2.5-hectare site that has optimal year-round growing conditions and access to all necessary infrastructure. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Joel Shacker
President

For further information, readers are encouraged to contact Joel Shacker, President, at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

CBD In Medicine: Relief and Regulation SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 11:40 AM on Tuesday, April 21st, 2020
  • Neuropharmacologist and Functional Medicine practitioner Dr Elisabeth Philipps tells MCN about the therapeutic benefits of CBD and talks about CBD regulation.

MCN speaks to Dr Philipps about the science behind the health benefits of CBD and the need for standardised regulation of CBD food supplements.

Dr Elisabeth Philipps is a neuropharmacologist and practitioner in Functional Medicine with over 18 years’ experience. She operates a thriving health consultancy in the UK specialising in CBD, brain and gut health; where she provides expert opinion for private clients, corporate business programmes, the national media, specialist healthcare publications and health companies.

How did you first become aware of the endocannabinoid system and the therapeutic benefits of cannabis?

I’m a neuropharmacologist by training, so I’ve been aware of the medicinal therapeutic benefits of cannabis for a number of years. The endocannabinoid system was only discovered in the 1990s so it’s actually a relatively recent system that we’ve known about in the body, but it’s only been in the last two to three years that my focus has become much more intense on the endocannabinoid system, medicinal cannabis and CBD oil supplements; because of the rise in profile of those products.

What are the potential dietary benefits of consuming CBD or hemp?

The two products are quite different: hemp is extract of the whole plant, so the dietary benefits of hemp normally come from the hemp seed – you could have the seeds ground or sprinkled on top of your food, for example; maybe hemp seed oil which makes a good salad dressing. Hemp oil extracts are rich in very beneficial omega-3 and omega-6 essential fatty acids; you also find things like protein and fibre as well as minerals and vitamins: magnesium and phosphorus, for example, are found within the hemp seeds themselves.

CBD is an even more refined extract from the hemp plant flowers rather than the seeds, so there’s not so much [in the way of] dietary benefit; but it contains the compounds such as the phytocannabinoids, and other compounds such as flavonoids and terpenes, which can confer health benefits; so you get the dietary benefits from hemp seeds and hemp seed oil and you get other health benefits from consuming CBD.

What kind of conditions and ailments do you find that people are using CBD for?

[There are] three primary areas that people find CBD works for them: the sleep area, to help improve the quality of sleep; people report being able to [get to] sleep more easily, stay asleep and feel more refreshed when they wake up. [The second area is] pain, which comes in many different forms – it can be nerve pain or neurogenic pain or inflammatory pain, so conditions such as arthritis, for example, or more acute conditions such as sporting injuries or general inflammatory injuries. People report taking CBD oil as helping to reduce the response to pain. What’s been very interesting in the study of CBD and phytocannabinoids in pain pathways is that not only is it blocking the pain pathways themselves in the spinal cord and brain, but also CBD acts within the parts of the brain that helps change our perception of pain. That’s really key, because it’s how we respond to the pain signals in our bodies that gives us the intensity of the experience; so CBD is an important component of a programme to help manage different types of pain.

The third area that I find CBD can really help is in mood, in particular [for patients who are] feeling anxious or stressed. CBD has this ability, through various pathways in the brain, to help balance the systems that help us feel better, to improve wellbeing, to improve our mood. CBD works at the neurotransmitter level, transmitting chemicals in the brain that send signals to help provide a balance. There are a number of studies coming in: they’re relatively small scale, but they’re looking at CBD oil for anxiety and for sleep and they have showed improvement in those areas; but the science is beginning to play catch-up now as well.

What is the science behind the effects of CBD on different symptoms?

CBD interacts with our own endocannabinoid system and I think that’s really key, because when you take a medicine it’s a very blunt tool: it either turns something on or turns something off; it blocks a response or it produces a response. CBD is lot more subtle than that within the body, because it works within the endocannabinoid system and that system is spread throughout our body – the endocannabinoid system is in the gut, the brain, in the immune cells, in the lungs, in the skin – so that’s why CBD can have such a diverse number of effects.

We produce our own cannabinoids within the body to stimulate and produce effects; and CBD helps balance the body’s production and the body’s ability to activate the endocannabinoid system through its own naturally produced mediators. There’s a lot of science showing how CBD acts within the endocannabinoid system and produces its responses.

What advice do you have for consumers when choosing a brand or product to ensure it is good quality and does not contain any unlisted ingredients?

This can be a very confusing area, because there are so many products that have hit the market. First of all, a CBD food supplement is legal in the UK if it contains less than 0.2% THC or tetrahydrocannabinol. That is the cannabinoid which causes the commonly associated high or buzz that you get from marijuana; it’s only present in hemp in very low levels anyway and it’s been stripped out of CBD oil. You need to ensure that you’re taking a legal product that contains less than 0.2% THC; and you can do that by asking the company for a certificate of analysis.

Every batch of CBD oil that a reputable company receives will have had a third-party laboratory testing [conducted] on that particular batch of oil, which will have a batch number so it can all be traced. That will show the breakdown of the different cannabinoids and the different constituents of that particular oil so you’ll be able to see not only that it contains the legal limit or less of THC, but the amount of CBD that it says on the label as well – that’s where the product can vary drastically, so you need to have a look at that certificate of analysis to show that it contains the CBD that you want. You will find some companies selling 0% THC products, which are very useful especially if you are drug tested for work or if you’re a professional athlete. The Banned Substances Control Group (BSCG) can test for THC and other banned substances and can provide a certificate to show that you don’t have any of those substances within your product. Reputable companies should have their certificates of analysis on their websites; or have a chat with them and they should provide that information for you.

How do you anticipate the market will evolve in over the next few years?

This is a very interesting time for CBD and medical cannabis: there’s obviously a lot going on and there’s a lot in the news. I think there needs to be more CBD regulation within the industry, because there’s a wide range of products on the market that differ in terms of their CBD content and what they purport to have in them; so there needs to be more CBD regulation, there’s no doubt about that. Equally [there is a question of] how that CBD regulation is brought in: the industry is playing catch-up in a way because the popularity of the product has grown exponentially in the last few years.

What we need to see is regulation, working with food standards agencies and [other regulators] at a government level. I think that will evolve over the next few months and years; and it’s going to be [because of] FourFive and other reputable companies that are working with the regulators, to help the industry in a way that protects it and still provides consumers with quality products.

Working on the assumption that further CBD regulation is likely to be introduced, do you expect this to impact patients using these products?

There is no doubt that the CBD regulation will change; and that it needs to protect the industry in terms of protection of products and protect consumers as well. I think it’s a case of companies and experts working with both agencies and the regulators: the impact on patients is our primary concern; and we are working towards avoiding any impact so there is seamless availability of quality products on the market. That is a goal that everyone is working to at the moment: every country is different and we’re just going to have to keep working together to make sure that high quality products [are going] to be readily available.

Do you anticipate Brexit having an impact, either positive or negative, on CBD regulation and medicinal cannabis regulation?

Brexit will potentially free up time and space for this topic to be higher up agendas. I believe that Brexit has possibly moved discussions of CBD and medical cannabis off the table or further down the list [of priorities]. I do think we’ll see more discussions happening in the next few weeks and months as Brexit resolves. At the moment we’re still working under European guidelines, in terms of the food supplement side at least, but it will be interesting to see how that pans out as we leave Europe; and as with many different areas of Brexit it’s still a bit of an unknown as to how EFTA’s [the European Free Trade Association] regulations and rules will affect the Food Standards Agency on the UK side. There will definitely be more discussion around this, certainly in the groups that I’m involved with; and we know that there are greater discussions to be had in the next few months.

Dr Elisabeth Philipps
Nutritional Therapist
www.hartwellnutrition.co.uk

SOURCE: https://www.healtheuropa.eu/cbd-in-medicine-relief-and-regulation/99418/

MOTA Ventures $MOTA.ca Generates $4.29 Million in Revenue During March 2020 $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 9:23 AM on Monday, April 20th, 2020
Mota large
  • Generated CAN$4,290,000 with related expenses of $4,240,000
  • The Immune Support product line experienced further positive growth contributing to First Class acquiring 20,959 new customers during the month of March

VANCOUVER, BC / ACCESSWIRE / April 18, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTCPINK:PEMTF) (the “Company“) is excited to announce that for the month of March 2020, its First Class CBD brand achieved sales of Cdn$4,290,000, with related expenses of Cdn$4,240,000. Customer acquisition expenses for March 2020 include one-time costs of approximately Cdn$1,160,000 associated with the introduction of the new line of Immune Support and CBD products. The Immune Support product line experienced further positive growth contributing to First Class acquiring 20,959 new customers during the month of March. The all-natural Immunity Blend is made from 100% pure essential oils, including cinnamon leaf, lemon, clove bud, lime, eucalyptus globulus, rosemary, peppermint, spearmint and oregano. The Company also launched an Immune CBD oil, along with an Elderberry Gummy product. The new Immune CBD product contains CBD, B3, B12, Vitamin C and Zinc. Sales for March 2020 compare to sales of Cdn$1,280,000 during the same period last year, representing an increase of 235%.

The Company also introduced a new brand, Nature’s Exclusive CBD, in the first week of April 2020. The Nature’s Exclusive CBD brand will offer a range of products, which include the new Immune CBD oil, Elderberry gummies, CBD oil drops, CBD gummies, CBD pain relief cream, CBD skin serum and CBD coffee.

First Class offers a CBD hemp-oil formulation intended to provide users with therapeutic benefits that hemp may offer. The hemp oil used in the products is derived from hemp grown and cultivated in the United States. The extraction process is designed to maintain all the beneficial qualities that hemp may offer. First Class offers a range of products, which include CBD oil drops, CBD gummies, CBD pain relief cream, CBD skin serum and CBD coffee. First Class plans to continue its significant growth in their U.S. operations over the balance of 2020, as well as an expansion into the European market.

“I am extremely pleased with the performance of our business during March 2020, a month where the world and the economy faced immeasurable challenges. Our ability to efficiently innovate and launch new products, is a perfect example of our primary competitive advantage, and what allows us to be a leader in the ecommerce space. We expect our investment in accelerated customer acquisition from February to March, including a one-time cost of Cdn$1,160,000, will continue to produce significant revenue growth, and are hopeful it will lead to increased profitability in the upcoming months,” stated Ryan Hoggan, CEO of the Company.

The Company cautions that figures for revenue, expenses and margin generated from the sale of First Class CBD products have not been audited, and are based on calculations prepared by management. Actual results may differ from those reported in this release once these figures have been audited. These figures were translated from US dollars into Canadian dollars using the Bank of Canada monthly average exchange rate of US$1.00:Cdn$1.3953 for March 2020 and US$1.00:Cdn$1.3368 for March 2019.

About Mota Ventures Corp.

Mota is an established ecommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the Company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its First Class CBD and Nature’s Exclusive brands. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Mota Ventures $MOTA.ca Announces Record Number of Subscriptions Year-To-Date in March and Over 6,000 New Customers in April $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 7:38 AM on Tuesday, April 14th, 2020
Mota large
  • First Class CBD and Nature’s Exclusive brands acquired over 6,000 new customers from April 1st through April 11th.
  • 1,700 of the new customers purchased products from the Immune Support line.
  • MOTA experienced a record number of new customers enrolling in a monthly subscription, totaling 18,962.

VANCOUVER, BC / ACCESSWIRE / April 14, 2020 / Mota Ventures Corp. (CSE:MOTA FSE:1WZ:GR OTC PINK:PEMTF) (the “Company“) is excited to announce its First Class CBD and Nature’s Exclusive brands acquired over 6,000 new customers from April 1st through April 11th. Additionally, during this time period over 1,700 of the new customers purchased products from the Immune Support line. During the month of March, the Company experienced a record number of new customers enrolling in a monthly subscription, totaling 18,962.

The Immunity Blend is currently the Company’s top seller in the Immune Support line. The all-natural blend is made from 100% pure essential oils, including cinnamon leaf, lemon, clove bud, lime, eucalyptus globulus, rosemary, peppermint, spearmint and oregano. The line also features Immune CBD oil containing CBD, B3, B12, Vitamin C and Zinc and Immunity Gummy Bears contain 100% natural Elderberry extract.

First Class and Nature’s Exclusive offer a CBD hemp-oil formulation intended to provide users with the therapeutic benefits that hemp may offer. The hemp oil used in the products is derived from hemp grown and cultivated in the United States. The extraction process is designed to maintain all the beneficial qualities that hemp may offer. First Class and Nature’s Exclusive offers a range of products, which include CBD oil drops, CBD gummies, CBD pain relief cream, CBD skin serum and CBD coffee. The Company plans to continue its significant growth in U.S. operations over the balance of 2020, as well as an expansion into the European market.

“I am pleased at the incredible number of monthly subscriptions acquired during the month of March. We continue to see overwhelming interest in our Immune Support products and higher CBD content oils. We operate a very responsive and agile business, which allows us to identify consumer trends and execute upon the demand we are seeing in the marketplace,” stated Ryan Hoggan, CEO of the Company.

About Mota Ventures Corp.

Mota Ventures is an established eCommerce direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its First Class CBD and Nature’s Exclusive brands. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.

Ryan Hoggan

Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Mota Ventures $MOTA.ca Acquires Interest in Folium Life Sciences $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 8:25 AM on Wednesday, April 8th, 2020
Mota large
  • Folium is a Health Canada licensed cannabis cultivator with facilities located on Vancouver Island.
  • Folium is nearing completion of the expansion of its existing cultivation facility, a further phase 2 expansion of the facility is expected.

VANCOUVER, BC / April 8, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTCPINK:PEMTF) (the “Company“) is pleased to announce that it has acquired (the “Acquisition“) all of the outstanding share capital of 1244780 B.C. Ltd. (the “Target“). The Acquisition was completed pursuant to a share exchange agreement (the “Purchase Agreement“), dated April 7, 2020, and entered into with an arms-length third-party (the “Vendor“). The sole asset of the Target consists of a 20% equity interest in Folium Life Sciences Inc. (“Folium“), which is in the process of developing a licensed indoor cannabis production facility located on Vancouver Island. In consideration for the Acquisition, the Company has issued 21,000,000 common shares.

Folium is a Health Canada licensed cannabis cultivator with facilities located on Vancouver Island. Folium is nearing completion of the expansion of its existing cultivation facility. Its business plan calls for a further phase 2 expansion of the facility. Folium aims to produce a high quality and consistent cannabis product through its facilities.

“Canada has been a pioneer in legalization and early adoption of cannabis for both recreational and medical purposes. This equity position in a well-capitalized licensed producer provides Mota with a sound financial investment in the sector.” stated Ryan Hoggan, CEO of the Company.

Each of the Vendor, the Target, and Folium are at arms-length from the Company. The Acquisition does not constitute a fundamental change for the Company, nor has it resulted in a change of control of the Company within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. In connection with completion of the Acquisition, the Company has issued 210,000 common shares (the “Administrative Fee Shares“) to a consultant who assisted with the Acquisition.

About Mota Ventures Corp.

Mota Ventures is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value-added products from its Latin American operations and distribute it both domestically and internationally. Its existing operations in Colombia consist of a 2.5-hectare site that has optimal year-round growing conditions and access to all necessary infrastructure. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Joel Shacker
President

For further information, readers are encouraged to contact Joel Shacker, President, at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Cannabis Expo London 2020 – Experience the Europe Canna Expo SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 4:36 PM on Monday, April 6th, 2020

SPONSOR: Mota is seeking to become a vertically integrated global CBD brand. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota. Combined total sales of almost $29,000,000 with a EBITDA of approximately 12.5% (2019) . Click Here for More Info

Mota large

With the current climate of social distancing and uncertainty, it’s no surprise that events have been forced to cancel or postpone left, right, and centre. Despite the disruption caused by the Coronavirus pandemic, some organisers are persevering with their plans – at least for the time being. One of those events is the Europe Canna Expo, set to take place in  London in July.

The Europe Canna Expo (ECE) is scheduled to make a return to London for a 2-day event on 26-27 July. Following the success of last year’s Europe CBD expo at the same location, the ECE will aim to bring together over 90 speakers and 125 exhibitors.

The Venue

The ECE is set to make a return to the London ExCel Centre in Canning Town East London. The event was held at the venue in July 2019, with an array of exhibitors and speakers. This year, the Europe Canna Expo is expected to be even bigger. However, uncertainty remains over the event.

The ExCel Centre is currently home to the temporary Nightingale hospital – the improvised care centre for victims of the Coronavirus. It remains unclear when the need for the venue will be over as the UK’s Coronavirus lockdown continues.

Exhibitors and Speakers

However, should the expo go on as planned, attendees will be spoilt for choice with speakers and professionals set to provide insights into the CBD, cannabinoid, and medical cannabis industries. In addition, the event will be present a huge number of exhibitors including a variety of manufacturers and businesses.

Speakers will include international experts showcasing senior-level insights and global scientific research in the CBD, cannabinoid and medical cannabis sectors. Organisers of the event expect that attendees will include consumers and businesses, as well as policymakers and press.

The event will provide an opportunity for global leading brands to showcase their products to thousands of attendees. From CBD drinks and chocolates to medicinal products, the Europe Canna Expo plans to present the most innovative international brands.

Event Schedule

The ECE organisers are yet to release a detailed schedule for the two-day cannabis expo. This may be due to the ongoing uncertainty surrounding the Coronavirus lockdown. For more information and up-to-date announcements, visit the ECE London website.

https://canex.co.uk/cannabis-expo-2020-europe-canna-expo-london/

Mota Ventures $MOTA.ca Acquires Over 20,000 Customers in March, Launches New Immune Support Product Line $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 9:13 PM on Sunday, April 5th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/Mota-Square-Logo-For-Blog-3.jpg
  • Immune Support product line has been received exceptionally well by consumers
  • The total number of customers acquired by First Class CBD in March 2020 is 20,959, including 6,419 immune customers
  • Initial average spend of Cdn$218.40 per customer

VANCOUVER, BC / April 4, 2020 Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC:PEMTF) (the “Company” or “Mota“) is pleased to provide an update on the recent progress that is fueling the increase in sales for products under its First Class CBD brand. The Immune Support product line has been received exceptionally well by consumers since it launched on March 14, 2020 and has been a significant driver of growth in March. The total number of customers acquired by First Class CBD in March 2020 is 20,959, including 6,419 immune customers with an initial average spend of Cdn$218.40 per customer.

The Company will be launching a new brand, Nature’s Exclusive CBD on April 6, 2020. The new Nature’s Exclusive CBD brand will introduce a line of Immune Support and CBD products with a higher content of CBD. The Company also anticipates releasing March 2020 financial results for First Class CBD in the next few days.

“The month of March has been exceptional, with new customer signups exceeding expectations. We believe this is a testament to our ability to adapt to the fast-paced eCommerce sector and ability to identify upcoming trends in consumer demand. I am very excited with the rapid progress and look forward to releasing March results in the upcoming days,” stated Ryan Hoggan, CEO of the Company.

The initial average spend per customer was translated from US dollar into Canadian dollar using the Bank of Canada average exchange rate of 1.3953 for March 2020.

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its First Class CBD and Nature’s Exclusive brands. Within Europe, its Satavida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.
Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President, at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Mota Ventures $MOTA.ca Acquires Over 20,000 Customers in March, Launches New Immune Support Product Line $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM-JC at 12:19 PM on Saturday, April 4th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/Mota-Square-Logo-For-Blog-3.jpg
  • Immune Support product line has been received exceptionally well by consumers
  • The total number of customers acquired by First Class CBD in March 2020 is 20,959, including 6,419 immune customers
  • Initial average spend of Cdn$218.40 per customer

VANCOUVER, BC / April 4, 2020 Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC:PEMTF) (the “Company” or “Mota“) is pleased to provide an update on the recent progress that is fueling the increase in sales for products under its First Class CBD brand. The Immune Support product line has been received exceptionally well by consumers since it launched on March 14, 2020 and has been a significant driver of growth in March. The total number of customers acquired by First Class CBD in March 2020 is 20,959, including 6,419 immune customers with an initial average spend of Cdn$218.40 per customer.

The Company will be launching a new brand, Nature’s Exclusive CBD on April 6, 2020. The new Nature’s Exclusive CBD brand will introduce a line of Immune Support and CBD products with a higher content of CBD. The Company also anticipates releasing March 2020 financial results for First Class CBD in the next few days.

“The month of March has been exceptional, with new customer signups exceeding expectations. We believe this is a testament to our ability to adapt to the fast-paced eCommerce sector and ability to identify upcoming trends in consumer demand. I am very excited with the rapid progress and look forward to releasing March results in the upcoming days,” stated Ryan Hoggan, CEO of the Company.

The initial average spend per customer was translated from US dollar into Canadian dollar using the Bank of Canada average exchange rate of 1.3953 for March 2020.

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its First Class CBD and Nature’s Exclusive brands. Within Europe, its Satavida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.
Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President, at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the anticipated launch of products under the First Class CBD brand, the financial results of First Class CBD, its plans to become a vertically integrated global CBD brand, its plans to cultivate and extract cannabis to produce CBD and high-quality value added CBD products in Latin America for distribution domestically and internationally. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

CLIENT FEATURE: Mota Ventures $MOTA.ca Continues to Define the European CBD Market $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 1:27 PM on Friday, April 3rd, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

RECENT HIGHLIGHTS

  • Immune Support Product Line Launched on March 14, 2020 Acquired over 5,500 new customers seeking natural solutions to help support their family’s immune systems, yielding an average initial order value of $189.00 USD.
  • First Class CBD brand achieved sales of Cdn$2,981,000 February 2020
  • Marketing efforts improved gross margins by 4.9% from January 2020 to February 2020.
  • February 2020 revenue represents an increase of 832% over the same period last year.
  • Plans to continue growth of First Class in the United States over the balance of 2020, as well as an expansion into the European market.

Formalized Joint Venture With Bevcanna Enterprises: Read More

Will share equal ownership in the Joint Venture and will be jointly responsible for developing and funding its operations

Company will provide manufacturing, marketing and distribution infrastructure in the European market.

Parties have determined an initial product launch and will provide further details on specific regions and timing once finalized

Formalized Collaboration for Sativida US Expansion Read More 

Acquired the intellectual property and trade names of Sativida

Unified Funding will provide assistance to Sativida with product sourcing, packaging, shipping, payment infrastructure and marketing

Sativida has become the number one search-ranked online retailer of CBD products in Spain and Mexico

Entered into Licensing Agreement with Phenome One Read More

A privately held full-service live genetic and seed preservation cannabis company.

Mota will have full access to Canada’s largest live genetic cannabis library with over 350 cultivars

Mota will have the right to propagate, cultivate, harvest and process a minimum of 10 selected cultivars

2 World Class Brands:

#1. FIRST CLASS CBD: ONE OF THE LARGEST US BASED ONLINE RETAILERS OF CBD PRODUCTS

HIGHLIGHTS:

  • Leader in online CBD sales in North America
  • Crop to package model: US grown CBD hemp
  • Acquired at a 1.5 times revenue valuation
  • Current customer base 142,000 customers -with additional leads of over 424,000 potential new customers
  • 2019 Sales of $19.2M USD/ EBITDA of 2.7M USD

  #2. SATIVIDA: ONLINE DIRECT TO CONSUMER RETAILER OF A VAST RANGE OF ORGANICE CBD OILS AND COSMETICS

HIGHLIGHTS:

  • Current distributor of CBD products in Spain, Portugal, Austria, Germany, France and the United Kingdom
  • Number one search-ranked online retailer in Spain and Mexico
  • Award winning product line known for its minimal heavy metal content and accurate CBD levels
  • 100% organic products

About Mota Ventures Corp.

Mota Ventures is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value added products from its Latin American operations and distribute it both domestically and internationally. Mota has established distribution networks through the acquisition of First Class CBD in the United States and Sativida in Europe. Mota Ventures is also seeking to acquire revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

Hub on Agoracom

FULL DISCLOSURE: Mota Ventures. is an advertising client of AGORA Internet Relations Corp.